Recently, there have been several reports showing how SPR promotes cancer progression in neuroblastoma (Lange et al., 2014; Yco et al., 2015), hepatocelluar carcinoma (Wu et al., 2020), as well as breast (Zhang et al., 2020) and ovarian (Cho et al., 2011) cancers. This evidence concerns the gene SPR and neuroblastoma.